A detailed history of Avanza Fonder Ab transactions in Alkermes Plc. stock. As of the latest transaction made, Avanza Fonder Ab holds 7,327 shares of ALKS stock, worth $212,776. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,327
Previous 8,220 10.86%
Holding current value
$212,776
Previous $247 Million 16.87%
% of portfolio
0.01%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 12, 2026

SELL
$29.04 - $33.81 $25,932 - $30,192
-893 Reduced 10.86%
7,327 $205 Million
Q3 2025

Oct 16, 2025

BUY
$26.13 - $30.46 $2,194 - $2,558
84 Added 1.03%
8,220 $247 Million
Q1 2025

Apr 15, 2025

BUY
$28.08 - $36.0 $228,458 - $292,896
8,136 New
8,136 $266 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.77B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Avanza Fonder Ab Portfolio

Follow Avanza Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avanza Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Avanza Fonder Ab with notifications on news.